Summary A series of human embryo fibroblasts has previously been shown to display increasing resistance to the antimetabolites methotrexate (MTX) and N-phosphonacetyl-L-aspartate (PALA) with increasing tumorigenicity. This increased resistance was found to be further increased as a result of salvage pathway activity for purine and pyrimidine biosynthesis. A similar pattern of increasing resistance paralleling increasing tumorigenicity has now been shown to occur with 5-fluorouracil (5-FU), which is independent of salvage pathway activity. The KMS normal cell line was found to be more sensitive to 5-FU than either the immortalised KMST or tumorigenic KN-NM cell lines. Immunohistochemical analysis of the three cell lines demonstrated high levels of p53 protein in the KMST and KN-NM cell lines, but undetectable p53 levels in the KMS cell line. From these data it was hypothesised that a difference in p53 function may be causing the difference in the patterns of sensitivity observed in the three cell lines. P53 is now believed to function as a regulator of a GI to S cell cycle checkpoint and as an inducer of apoptosis following DNA damage to the cell.
The resistance of tumour cells to chemotherapeutic agents is a major clinical problem in the treatment of human malignancy. Many mechanisms of resistance have been postulated and studied (Fox et al., 1991) . In the past, resistance of tumour cells to certain members of the antimetabolite group of drugs has been attributed to either gene amplification (Schimke et al., 1977; Wahl et al., 1979) or the increased activity of the salvage pathways for purine and pyrimidine biosynthesis (Weber 1983; Kinsella and Haran, 1991) .
In fact previous work from this group has demonstrated differences in the sensitivity of series of human embryo fibroblast cell lines of common genetic origin, to the chemotherapeutic antimetabolites methotrexate (MTX) and N-phosphonacetyl-L-aspartate (PALA). This sensitivity could be greatly decreased by the activity of the salvage pathways for purine and pyrimidine biosynthesis (Kinsella and Haran, 1991; Pickard and Kinsella, 1995) . A similar pattern of resistance was observed with 5-fluorouracil (5-FU), with the KMS normal cell line being more sensitive than either the KMST or KN-NM cell lines. However, the increased resistance of the KMST and KN-NM cell lines to 5-FU was shown to be unaltered in the presence of the nucleoside transport inhibitor dipyridamole (Pickard and Kinsella, 1995) and thus was independent of salvage pathway involvement.
Progression towards the tumour phenotype results from the interaction of dominantly acting oncogenes and tumoursuppressor genes. It is becoming increasingly clear that the cytotoxic action of many anti-cancer drugs involves processes downstream of the interaction between a particular drug and its target. It has been postulated that the outcome of drug therapy is determined by the response of a particular cell according to its phenotype, rather than by the nature of the primary drug-target interaction alone (Dive and Hickman, 1991) .
Alterations in p53 are the most common genetic aberrations found so far in human malignancies (Hollstein et al., 1991; Levine et al., 1991) . P53 protein levels are not normally detectable by immunohistochemical techniques, owing to the relatively short half-life of the p53 protein in the cell nucleus (Finlay et al., 1988) . It is only when the p53 protein becomes stabilised or overexpressed that the protein becomes detectable immunohistochemically. Stabilised p53 is now thought to reflect a change in the environment of the cell which affects, either directly or indirectly, the p53 protein and indicates an inactivated or impaired function in that particular cell. The tumour-suppressor gene p53 protein product is believed to serve as a critical regulator of a GI cell cycle checkpoint and as an inducer of apoptosis following exposure of cells to DNA-damaging agents (Katsan et al., 1991; Fritsche et al., 1993; Nelson and Kastan, 1994) . DNA damaging agents, including those used in cancer chemotherapy, have been reported to induce nuclear accumulation of wild-type p53 in fibroblasts of both mouse and human origin (Lowe and Ruley 1993; Fritsche et al., 1993) (Lane, 1992) . Recently immature mouse thymocytes lacking p53 have been shown not to undergo apoptosis when exposed to ionising radiation and demonstrate increased resistance to these lethal effects (Lowe et al., 1993a) . Studies in certain human tumour cells lacking p53 have also demonstrated increased resistance to ionising radiation as a result of the loss of GI checkpoint control (Mcllwrath et al., 1994; Lee and Bernstein, 1993) .
It has been postulated that it is the ability or failure of a cancer cell to undergo apoptosis which is an important determinant of the therapeutic response of that cell to insult (Dive and Hickman, 1991; Lowe et al., 1993b) . Chemotherapeutic agents including 5-FU along with irradiation and certain hormonal therapies are known to induce apoptosis or programmed cell death in certain cell types (Dive and Hickman, 1991; Lowe et al., 1993b (Raff, 1992) and protects against cancer (Williams, 1991) . Genes known to participate in the regulation of apoptosis are EIA (Rao et al., 1992; White et al., 1992; Ruley 1993), myc (Evan et al., 1992) , bcl-2 (Hockenberry et al., 1990; Chiou et al., 1994) , p53 (Lowe et al., 1993a; Clarke et al., 1993) and possibly ras.
In the present study we have investigated the difference in resistance observed between the cell lines to 5-FU and tried to establish the basis of this difference. Whether the differences are a result of differing p53 functionality causing differences in apoptosis levels or cell cycle arrest will be discussed along with its implications for malignancy.
Materials and methods

Cell lines
The cell lines used were the normal human embryo fibroblast cell line KMS-6, its cobalt-60-irradiated immortalised derivative KMST (Namba et al., 1988 ) and the tumorigenic cell line KN-NM established from the KMST cell line by transfection with an activated N-ras oncogene cDNA (Kinsella et al., 1990) . This series of cell lines was chosen as a model for the progression of a normal cell towards tumorigenicity as is observed in vivo. All cell lines were routinely maintained in monolayer culture in Dulbecco's modified Eagle medium (Life Technologies, Paisley, UK) supplemented with 10% fetal bovine serum (ICN Biomedicals, Irvine, UK) and 200 mM glutamine at 37TC in a humid atmosphere of 5% carbon dioxide/95% air. Cells were routinely plated at a density of 5 x 105 per 75 cm2 tissue culture flask in 10 ml of medium and passaged approximately every 5 days by trypsinisation.
Clonogenic cell survival assays To assay for drug resistance (sensitivity) 500 test cells were plated onto a feeder layer of 5 x 104 gamma-irradiated (5000 rad) EJ human bladder carcinoma cells in a 1O cm tissue culture plate (5 plates per point) and allowed to attach for 4 h. These cell densities were established from preliminary experiments and reflect plating efficiencies over the range of 12.3% (KMS) to 26% (KMST and KN-NM) in control plates. After 4 h the medium was removed and replaced with medium containing 5-FU at the appropriate concentration over the range 1 x l0-7 to 1 x l0-4 M. The medium was replaced with drug-free medium after weeks 1 and 2. The plates were incubated for a total of 3 weeks to permit colony formation. After 3 weeks the medium was removed and any colonies present were fixed in ice-cold methanol for 15min and stained with 10% Giemsa stain. Colonies were counted and the colonies on the treated plates were expressed as a percentage of the colonies on control plates to which no drug had been added. These assays were not designed to try and recreate conditions experienced in vivo in the clinic. The exposure of the cells to drug for 1 week was longer than the exposure experienced by a cell in vivo and the doses used were at times superphysiological. With these assays an attempt was made to understand the basic mechanisms occurring in the cell which may be causing the difference in resistance observed. This particular assay was carried out on three separate occasions.
Immunohistochemical analysis for P53 protein Asynchronous log phase cultures of the KMS, KMST (Evans and Dive, 1993) . Five horizontal fields were viewed and the number of cells identified as apoptotic, viable and 'ghost' were counted. The number of apoptotic cells was expressed as a percentage of all the detached cells and this figure was used to adjust the haemocytometer cell count to give a final estimation of the total number of apoptotic cells in that sample. The ghost cell count was ignored in the final calculation because, although these cells had most likely been through the process of apoptosis, they were not at the time of measurement and hence not a true reflection of the level of apoptosis at that time.
Twenty flasks per cell line were run in parallel in order to determine the growth curve for the same cell population over the measured period and to enable the number of apoptotic cells at each dose to be expressed as a percentage of the total cell population. These flasks were incubated in identical conditions and trypsinised for counting every 48 h from time 0 to day 8 of the experiment. All experiments were carried out on at least three separate occasions and the results presented are of data from one representative experiment.
Measurement of cell cycle distribution The cell cycle distributions of the trypsinised monolayers (but not detached cells) were measured on days 3 and 6 of the experiment. Cell samples for flow cytometry were fixed in 1% paraformaldehyde and 1% Triton X-100 for 10 min before being washed and resuspended in phosphate-buffered saline (PBS). Propidium iodide (PI) (20 jtl of a 2.5 mg ml1 solution in PBS) and RNAse (10 itl of a 10 mg ml' solution) were added to 5 x I05 cells 500 ,l-I PBS for 30 min at 37°C. and were not altered for any of the subsequent drug-treated cell samples. This experiment was carried out on at least three separate occasions and at various other time points after drug addition. The data presented are from one representative experiment.
Results
P53 status of the three cell lines
The ABC peroxidase staining method was used to stain any p53 protein present in the cell nucleus (Figure 1 ). Brown coloration in the nucleus indicated the presence of p53 protein. Overexpression or stabilisation of the p53 protein results in levels that are detectable with immunohistochemistry. (Finlay et al., 1988; Gannon et al., 1990; Iggo et al., 1990) . Apart from slight background staining, the KMS cell line showed no signs of p53 protein overexpression, suggesting that this cell line possessed wild-type p53 function (Figure la  and b) . This was in contrast to both the KMST and KN-NM cell lines which showed definite brown nuclear staining, indicating p53 overexpression/stabilisation and possible disruption of p53 wild-type function ( Figure Ic-f Levels of apoptosis in the three cell lines Following initial experiments to establish the levels and rates of cell death, apoptosis was measured every 24 h for all three cell lines for a period of 8 days following drug addition. The drug was not removed from the medium at any time during this period. The control untreated cell populations showed levels of apoptosis ranging from negligible at<0.15% of the Drug rsistance as a function of cell cyce delay M Pickard et al 1393 total cell population in the KMS cell line to higher levels of 1.5 and 2.5% for KMST and KN-NM cell lines respectively (Figure 4) . High levels of apoptosis were observed in all three cell lines 6 days after continuous exposure to the highest drug concentrations of 1 x 10-3 M 5-FU, at levels of 52% of the total cell population in KMS, 51% in KMST and 42% in KN-NM (data from one representative experiment). However, a difference in the level of apoptosis was observed between the KMS normal cell line and the KMST and KN-NM cell lines in response to lower concentrations of 5-FU. At drug concentrations of 1 x 0-5 and 1 x 10-4 M, the KMS cell line showed negligible levels of apoptosis (Figure 4 ). These levels were in contrast to those seen in the KMST and KN-NM cell lines, at the same drug concentrations, which both demonstrated increasing levels of apoptosis through the 8 day period. The level of apoptosis appeared to increase in a dose-dependent manner with both the KMST and KN-NM cell lines reaching levels of 8.2% and 17.8% respectively, by day 8 at a concentration of 1 x 10-4 M (Figure 4) . 
Discussion
Previous studies from this group have shown that differences in the resistance of a series of human embryo fibroblasts to MTX and PALA can be greatly exaggerated by the involvment of the salvage pathways for purine and pyrimidine biosynthesis (Kinsella and Haran, 1991; Pickard and Kinsella, 1995) . A similar pattern of increasing resistance paralleling increasing tumorigenicity was observed for 5-FU, but as stated previously, was independent of salvage pathway involvement. No change in the resistance to 5-FU was observed in any of the three cell lines in the presence of the dipyridamole at a concentration of 5 gM. Dipyridamole has previously been shown to be an effective inhibitor of nucleoside transport (Berlin and Oliver, 1972; Paterson et al., 1980; Plagemann and Wolhueter, 1980; Young and Jarvis, 1983; Zhen et al., 1983) . A significant increase in the sensitivity of the KMST and KN-NM cell lines was observed when MTX and PALA were administered in the presence of dipyridamole (Pickard and Kinsella, 1995) . Immunohistochemical analysis revealed differences in the levels of p53 protein between the three cell lines. These data suggested that wild type-p53 function may have been disrupted in the immortalised KMST and the tumorigenic KN-NM cell lines (Figure 1) . Increased p53 protein stability in a (Gannon et al., 1990; Baas et al., 1994) . This association has recently been called into question following the publication of a number of studies suggesting false-positive and negative results (Borreson et al., 1991; Cripps et al., 1994 , 1991; Kuerbitz et al., 1992) .
DNA strand breaks are thought to be an important factor in initiating this DNA damage response pathway (Nelson and Kastan, 1994) . It has been postulated that the outcome of drug therapy will be determined by the response of the cell, according to its phenotype, rather than by the nature of the primary drug target interaction alone (Dive and Hickman, 1991) . The response of the cell can manifest itself in several ways including apoptosis (Clarke et al., 1993; Lowe et al., 1993b, c) , cell cycle arrest (Mcllwrath et al., 1994; Nelson and Kastan, 1994) or drug-induced increases in metastatic potential (McMillan and Hart, 1987) . This, together with the evidence for differences in p53 functionality between the cell lines, lead us to postulate that the differences in cell line sensitivity to 5-FU (Figure 2 ) may be the result of differing cellular responses to drug-induced damage. Contrary to expectation, measurement of apoptosis in the three cell lines showed the normal KMS cell line, with wild-type p53 protein levels, to apoptose at a lower level than the more resistant KMST and KN-NM cell lines. From these data it became clear that the differences in the levels of apoptosis between the cell lines could not explain the differences in resistance observed.
Detailed cell cycle analysis showed that the KMS cell line ceased to proliferate in response to increasing levels of 5-FU and appeared to be in some type of growth arrest. This was in contrast to both the KMST and KN-NM cell lines, which appeared to continue proliferating regardless of the insult. Representative cytograms and DNA histograms obtained for the three cell lines after 3 days' exposure to increasing concentrations of 5-FU can be observed in Figure 5 . This time point was independent of any influence of growth factor depletion or contact inhibition on the cell proliferation rate, as can be observed from the growth curves (Figure 3 ). All three cell lines showed classical cell cycle patterns in control Drug resistance as a function of cell cycle delay M Pickard et al drug-free medium, with a GI and G2 peak divided by cells in S-phase. The KMS normal cell line showed a decrease in the percentage of cells in S-phase with increasing 5-FU concentration, with a G1 arrest predominating at low drug concentrations and a G2/M arrest at higher drug concentrations. This type of response to presumed drug-induced DNA damage is the classical pattern for wild-type p53 function as first described by Kastan et al. (1991) . Cells that are already in S-phase at the time of DNA damage continue to progress through to G2/M, whereas cells in GI do not continue to enter S-phase. After 1 week of exposure the drug was removed from the cells. The KMS cells exposed to the two highest doses of 5-FU showed no signs of further proliferation and were confirmed to be in permanent growth arrest. One may predict that the amount of damage in these cells was at such a high level that the cells were held in a permanent state of growth arrest. Leonardo et al. (1994) have recently reported a similar permanent growth arrest response in human fibroblasts following ionising radiation. Thus, in addition to apoptosis and transient cell cycle arrest, permanent growth arrest may be a third type of cellular damage response. The immunohistochemical and cell cycle data are consistent with the KMS cell line having wild-type p53 function. This is in contrast to the situation seen with both the KMST and KN-NM cell lines. These cell lines demonstrated a dramatic increase in the percentage of cells in S-phase with increasing concentrations of 5-FU. The number of cells in both G1 and G2/M decreased with increasing 5-FU concentrations. These data, along with the KMST and KN-NM immunohistochemical data, therefore suggest that wild-type p53 function may have been lost from both these cell lines and that, especially at high doses of 5-FU, the cell cycle is well out of control.
The effect of the activated N-ras oncogene on the growth rate of the KN-NM cell line was easily recognisable ( Figure  3) . Growth was much more rapid and the cell number reached a much higher level in 8 days than the KMST cell line. Although proliferation was increased and colony formation was more substantial in the tumorigenic KN-NM cell line this appeared to have no effect on the overall resistance of the cell population to 5-FU (Figure 2 ).
In conclusion, these data have demonstrated an association between cell cycle changes and sensitivity to 5-FU. Normal cells appear to modulate this response by a permanent G1 arrest, with significant apoptosis only occurring at the highest doses of 5-FU. Contrary to expectation, the cells tending towards tumorigenicity underwent higher levels of apoptosis than the normal cells. This phenomenon may have been related to increasing levels of 5-FU and presumably DNA damage in cells lacking cell cycle control, resulting in spontaneous apoptosis as a result of a failure in mitosis. In this series of experiments, p53 was not artificially inserted into the cell lines, however both indirect immunohistochemical and direct cell cycle evidence suggests that wild-type p53 function has been lost by the cells tending towards tumorigenicity. This model is thought to be a good reflection of the situation actually occurring in vivo, as a cell progresses from its normal phenotype to one of a tumorigenic cell. These data demonstrate the effect of loss of cell cycle control, whether p53 dependent or not, in regulating the sensitivity of human cells to DNA-damaging agents. If cell cycle control is missing, as in the progression towards malignancy, then increasingly resistant phenotypes appear to result. Clearly the next experiments need to be conducted with the use of cells of known p53 status, employing the use of wild-type and mutant p53-containing vectors. 
